Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
F&O
Mutual Funds
Invest in Mutual Funds
Invest in direct mutual funds at zero charges via lump sump investments or SIPs
Nippon India Pharma Fund Direct Growth
+18.55%
3Y annualised
+0.87% 1D
NAV: 18 Sep '26
₹643.73
Min. for SIP
₹100
Fund size (AUM)
₹9,479.08 Cr
Expense ratio
0.99%
Rating
2
Return calculator
Monthly investment
₹5,000
| Over the past | Total investment | Would've become | Historic returns | Returns |
|---|---|---|---|---|
| 1 year | ₹60,000 | ₹65,430 | +9.05% | |
| 3 years | ₹1,80,000 | ₹2,18,439 | +21.36% | |
| 5 years | ₹3,00,000 | ₹4,61,748 | +53.92% | |
| 10 years | ₹6,00,000 | ₹15,98,908 | +166.48% |
Holdings (39)
| Name | Sector | Instruments | Assets |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 12.37% |
| Divi's Laboratories Ltd | Healthcare | Equity | 7.00% |
| Lupin Ltd | Healthcare | Equity | 6.43% |
| Cipla Ltd | Healthcare | Equity | 6.09% |
| Apollo Hospitals Enterprise Ltd | Healthcare | Equity | 5.15% |
| Dr. Reddy's Laboratories Ltd | Healthcare | Equity | 4.93% |
| Mankind Pharma Ltd. | Healthcare | Equity | 4.09% |
| Sai Life Sciences Ltd. | Healthcare | Equity | 3.94% |
| Ajanta Pharma Ltd | Healthcare | Equity | 3.47% |
| Glaxosmithkline Pharmaceuticals Ltd | Healthcare | Equity | 3.31% |
| Max Healthcare Institute Ltd | Healthcare | Equity | 2.92% |
| Ipca Laboratories Ltd | Healthcare | Equity | 2.84% |
| Vijaya Diagnostic Centre Ltd | Healthcare | Equity | 2.68% |
| Medplus Health Services Ltd | Healthcare | Equity | 2.51% |
| Thyrocare Technologies Ltd | Healthcare | Equity | 2.45% |
| Gland Pharma Ltd | Healthcare | Equity | 2.44% |
| Piramal Pharma Ltd | Healthcare | Equity | 2.25% |
| Repo | Unspecified | Repo | 2.14% |
| Abbott India Ltd | Healthcare | Equity | 2.13% |
| Dr. Lal Pathlabs Ltd | Healthcare | Equity | 2.04% |
| Alkem Laboratories Ltd | Healthcare | Equity | 1.82% |
| Narayana Hrudayalaya Ltd | Healthcare | Equity | 1.66% |
| Aurobindo Pharma Ltd | Healthcare | Equity | 1.63% |
| Pfizer Ltd | Healthcare | Equity | 1.57% |
| Syngene International Ltd | Healthcare | Equity | 1.48% |
| Suraksha Diagnostic Ltd. | Healthcare | Equity | 1.39% |
| Fortis Healthcare Ltd | Healthcare | Equity | 1.29% |
| Emcure Pharmaceuticals Ltd. | Healthcare | Equity | 1.25% |
| Anthem Biosciences Ltd. | Healthcare | Equity | 1.20% |
| Akums Drugs And Pharmaceuticals Ltd. | Healthcare | Equity | 1.11% |
| Biocon Ltd | Healthcare | Equity | 1.09% |
| Sanofi India Ltd | Healthcare | Equity | 0.99% |
| Sanofi Consumer Healthcare India Ltd | Healthcare | Equity | 0.93% |
| Indoco Remedies Ltd | Healthcare | Equity | 0.47% |
| Astrazeneca Pharma India Ltd | Healthcare | Equity | 0.46% |
| Molbio Diagnostics Ltd. | Healthcare | Equity | 0.44% |
| Concord Biotech Ltd. | Healthcare | Equity | 0.17% |
| Others Mrgn Money | Unspecified | Margin Money | 0.01% |
| Net Payables | Unspecified | Net Payables | -0.14% |
See All
Minimum investments
Min. for 1st investment
₹5,000
Min. for 2nd investment
₹1,000
Min. for SIP
₹100
Returns and rankings
Annualised returns
Absolute returns
| Name | 3Y | 5Y | 10Y | All |
|---|---|---|---|---|
| Fund returns | +18.6% | +13.8% | +15.7% | +17.6% |
| Category average (Equity Sectoral) | +22.1% | +14.6% | +12.0% | -- |
| Rank (Equity Sectoral) | 11 | 7 | 1 | -- |
Exit load, stamp duty and tax
Exit load
Exit load of 1% if redeemed within 1 month.
Stamp duty on investment: 0.005% (from July 1st, 2020)
from July 1st 2020
Tax implication
If you redeem within one year, returns are taxed at 20%. If you redeem after one year, returns exceeding Rs 1.25 lakh in a financial year are taxed at 12.5%.
Check past data
Fund management
ASAmber SinghaniaMar 2026 - PresentView details
AS
Amber Singhania
Mar 2026 - Present
View details
SRBSailesh Raj BhanJan 2013 - PresentView details
SRB
Sailesh Raj Bhan
Jan 2013 - Present
View details
KDKinjal DesaiMar 2026 - PresentView details
KD
Kinjal Desai
Mar 2026 - Present
View details
About Nippon India Pharma Fund Direct Growth
Nippon India Pharma Fund Direct Growth is a Equity Mutual Fund Scheme launched by Nippon India Mutual Fund. This scheme was made available to investors on 30 Jun 1995. Amber Singhania is the Current Fund Manager of Nippon India Pharma Fund Direct Growth fund. The fund currently has an Asset Under Management(AUM) of ₹7,97,966 Cr and the Latest NAV as of 18 Sep 2026 is ₹643.73.
The Nippon India Pharma Fund Direct Growth is rated Very High risk. Minimum SIP Investment is set to ₹100. Minimum Lumpsum Investment is ₹5,000. Exit load of 1% if redeemed within 1 month.
;
Investment Objective
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
Fund benchmarkBSE Healthcare Total Return Index
Fund house
Rank (total assets)#4 in India
Total AUM₹7,97,966.37 Cr
Date of Incorporation30 Jun 1995
Launch Date30 Jun 1995
Address30th Floor, One Lodha PlaceSenapati Bapat Marg, Lower ParelMumbai Mumbai 400013
Websitewww.karvymfs.com
AddressKarvy House, No. 46, 8-2-609/K, Avenue 4, Street No.1 Banjara Hills,